Yakovenko E P, Agafonova N A, Ivanov A N, Yakovenko A V, Aldiyarova M A, Volosheinikova T V, Grigoryeva Yu V, Soluyanova I P
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia.
Clinical Hospital, Department for Presidential Affairs of the Russian Federation, Moscow, Russia.
Ter Arkh. 2016;88(4):88-92. doi: 10.17116/terarkh201688488-92.
Rebamipide is a cytoprotесtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration. The major properties of rebamipide include stimulation of prostaglandins and synthesis of muсus glycoproteins, inhibition of reactive oxygen species, inflammatory cytokines, and chemokines, and suppression of neutrophil activation. This paper shows the ability of rebamipide to enhance the efficiency of therapy for Helicobacter pylori-induced infection, to reduce inflammation, including that after infection eradication, to accelerate ulcer healing, and to prevent the progression of preneoplastic lesions.
瑞巴派特是一种细胞保护药物，可刺激胃和小肠黏膜中内源性前列腺素的生成，并加速由幽门螺杆菌感染和非甾体抗炎药使用引起的糜烂和溃疡的愈合。瑞巴派特的主要特性包括刺激前列腺素和黏液糖蛋白的合成、抑制活性氧、炎性细胞因子和趋化因子以及抑制中性粒细胞活化。本文展示了瑞巴派特提高幽门螺杆菌感染治疗效果、减轻炎症（包括根除感染后的炎症）、加速溃疡愈合以及预防癌前病变进展的能力。
